Duplicate Document
This document appears to be a copy. The original version is:
Biopharmaceutical and Information Convergence Investment Performance Summary for New Leaf FundsBiopharmaceutical and Information Convergence Investment Performance Summary for New Leaf Funds
Biopharmaceutical and Information Convergence Investment Performance Summary for New Leaf Funds The passage provides internal fund performance metrics without mentioning any individuals, government entities, or controversial transactions. It lacks actionable leads, novel allegations, or connections to powerful actors, making it low-value for investigative purposes. Key insights: New Leaf invested $945M in 64 biopharma deals with a 2.29x gross multiple.; Information convergence sector saw $142M invested with a 2.62x gross multiple.; Returns are presented gross of fees; net returns are referenced elsewhere.
Summary
Biopharmaceutical and Information Convergence Investment Performance Summary for New Leaf Funds The passage provides internal fund performance metrics without mentioning any individuals, government entities, or controversial transactions. It lacks actionable leads, novel allegations, or connections to powerful actors, making it low-value for investigative purposes. Key insights: New Leaf invested $945M in 64 biopharma deals with a 2.29x gross multiple.; Information convergence sector saw $142M invested with a 2.62x gross multiple.; Returns are presented gross of fees; net returns are referenced elsewhere.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.